VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 1, 2012) - Eternity Healthcare Inc. (OTCBB:ETAH) (the "Company") a medical technology company, is pleased to announce today, that has received Health Canada approval for its needle-free injection device, the "Comfort-in®". The Comfort-in® has also been approved in Europe by the European regulatory bodies. Eternity Healthcare is further in the process of filling documentation for the FDA's approval in the United States.
About the Needle Free Injection Device
A unique technology which does not require needle for injecting medicine to the body. The technology ("Device") uses a high pressure infusion system that effectively delivers fluid to the body similar to needle, but it is not a needle. The technology has proven to be effective in administering greater than 95% of the medicine into the skin in less than a second. The technology is extremely fast, easy to use and pain-free. This technology is believed to be ideal for diabetes patients for the injection of insulin. According to American Diabetes Association there are 25.8 million diabetics in the United States. Currently the vast majority of these patients use insulin for treatment. Insulin must be injected daily, a cumbersome and unpleasant practice. The needle-free injection device should make insulin therapy convenient and patient friendly. The device could also be used to inject other types of medicines for vast variety of diseases and patients, as well as for painless vaccination.
About Eternity Healthcare
Eternity Healthcare is a publically listed company in the United States under the stock symbol of "ETAH". The Company is the leader in medical technologies with state of the art medical devices, including diagnostic kits, digital cholesterol readers, injection-free needles and many more. For further information visit the Company's website: www.eternityhealthcare.com
Notice Regarding Forward Looking Statements
This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.